Dyslipoproteinemia in women. Special considerations

Endocrinology and Metabolism Clinics of North America

Volumn 19, Issue 2, 1990, Pages 381-398

  Miller, V T ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

DYSLIPOPROTEINEMIA; FEMALE; HUMAN; MENOPAUSE; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 0025290011     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0889-8529(18)30331-1     Document Type: Review

References (82)

1. Ahrén T. Victor A. Lithell H. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins Contraception 28 1983 315
2. Austin M.A. Breslow J.L. Hennekens C.H. Low density lipoprotein subclass patterns and risk of myocardial infarction JAMA 260 1988 1917
3. Barrett-Connor E. Wingard D.L. Criqui M.H. Postmenopausal estrogen use and heart disease risk factors in the 1980's JAMA 261 1989 2095
4. Beard C.M. Fuster V. Annegers J.F. Reproductive history in women with coronary heart disease: A case-control study Am J Epidemiol 120 1984 108
5. Bengtsson C. Rybo G. Westerberg H. Number of pregnancies, use of oral contraceptives and menopausal age in women with ischemic heart disease, compared to a population sample of women Acta Med Scand 549 suppl 1973 75
6. Brunner D. Weislort J. Meshulam N. Relation of serum cholesterol percentage to the incidence of definitive coronary events: Twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study Am J Cardiol 59 1987 1271
7. Brunzell J.D. Austin M.A. Plasma triglyceride levels and coronary disease N Engl J Med 320 1989 1273
8. Burkman R.T. Robinson J.C. Kruszson-Moran D. Lipid and lipoprotein changes associated with oral contraceptive use: A randomized clinical trial Obstet Gynecol 71 1988 33
9. Bush T.L. Barrett-Connor E. Cowan L.D. Cardiovascular mortality and noncontraceptive estrogen use in women: Results from the Lipid Research Clinics Program Follow-up Study Circulation 75 1987 1102
10. Bush T. Cowan L. Heiss G. Ovarian function and lipid/lipoprotein levels Results from the Lipid Research Clinics (LRC) Program (abstract). Am J Epidemiol 120 1984 489
11. Bush T.L. Fried L.P. Barrett-Connor E. Cholesterol, lipoproteins and coronary heart disease in women Clin Chem 4 B 1988 B60
12. Bush T.L. Miller V.T. Effects of pharmacologic agents used during the menopause Mishell D.R. Jr Menopause: Physiology and Pharmacology 1987 Year Book Medical Publishers Chicago 197
13. Campos H. McNamara J.R. Wilson R.W.F. Differences in low density lipoprotein subfraction and apolipoproteins in premenopausal and postmenopausal women (Framingham) J Clin Endocrinol Metab 67 1988 30
14. Castelli W.P. The triglyceride issue: A view from Framingham Am Heart J 112 1986 432
15. Castelli W.P. Garrison R.J. Wilson P.F. Incidence of coronary heart disease and lipoprotein cholesterol levels JAMA 256 1986 2835
16. Chetkowski R.J. Meldrum D.R. Steingold K.A. Biologic effects of transdermal estradiol N Engl J Med 314 1986 1615
17. Chez R.A. Clinical aspects of three new progestogens: Desogestrel, gestodene and norgestimate Am J Obstet Gynecol 160 1989 1296
18. Colditz G.A. Willett W.C. Stampfer M.J. Menopause and the risk of coronary heart disease in women N Engl J Med 316 1987 1105
19. Colditz G.A. Bonita R. Stampfer M.J. Cigarette smoking and risk of stroke in middle-aged women N Engl J Med 318 1988 937
20. Criqui M.H. Heiss G. Cohn R. Triglycerides and coronary heart disease mortality: The Lipid Research Clinics Follow-up Study, (abstract) CVD Epidemiol Newsl 41 1987 13
21. Crouse J.R. Parks J.S. Schey H.M. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease J Lipid Res 26 1985 566
22. Davidoff F. Tishler S. Rosoff C. Marked hyperlipidemia and pancreatitis associated with oral contraceptive therapy N Engl J Med 289 1973 552
23. Desoye G. Schweditsch M. Pfieffer K.P. Correlations of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum J Clin Endocrinol Metab 64 1987 704
24. Eichhorn D. Justus B. Jaross W. The effect of ovariectomy on lipoprotein metabolism during a period of one year Exp Clin Endocrinol 88 1983 212
25. Fâhraeus L, Larsson-Cohn U, Wallentin L: Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy Obstet Gynecol 66 1985 468
26. Garrison R.J. Kännel W.B. Feinlieb M. Cigarette smoking and HDL cholesterol Atherosclerosis 30 1978 7
27. Glueck C.J. Scheel D. Fishback J. Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia Metabolism 21 1972 657
28. Goldzieher J.W. Pharmacology of contraceptive steroids: A brief review Am J Obstet Gynecol 160 1989 1260
29. Gordon D.J. Probstfield J.L. Garrison R.J. High-density lipoprotein cholesterol and cardiovascular disease Circulation 79 1989 8
30. Gordon T. Kännel W.B. Hjortland M.C. Menopause and coronary heart disease: The Framingham Study Ann Intern Med 89 1978 157
31. Haynes S.G. Feinleib M. Women, work and coronary heart disease: Prospective findings from Framingham Study Am J Public Health 70 1980 133
32. Hirvonen E. Mälkonën M. Manninen V. Effect of different progestogens on lipoproteins during postmenopausal replacement therapy N Engl J Med 304 1981 560
33. Inman W.H.W. Vessey M.P. Westerholm B. Thromboembolic disease and the steroidal content of oral contraceptives: A report of the Committee on Safety of Drugs Br Med J 2 1970 203
34. Kännel WB: Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study Am Heart J 114 1987 413
35. Kännel WB: Lipids, diabetes and coronary heart disease: Insight from the Framingham Study Am Heart J 110 1985 1100
36. Kay C.R. The happiness pill? J R Coll Gen Pract 30 1980 8
37. Kim H-J, Kalkhoff RK: Changes in lipoprotein composition during the menstrual cycle Metabolism 28 1979 663
38. Kirkland R.T. Keenan B.S. Probstfield J.L. Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence JAMA 257 1987 502
39. Knopp R.H. Bergelin R.O. Wahl P.W. Population-based lipoprotein lipid reference values for pregnant women compared to non-pregnant women classified by sex hormone usage Am J Obstet Gynecol 143 1982 626
40. Knopp R.H. Montes A. Childs M. Metabolic adjustments in normal and diabetic pregnancy Clin Obstet Gynecol 24 1981 21
41. Korenman S.G. Sherman B.M. Korenman J.C. Reproductive hormone function: The perimenopausal period and beyond Clin Endocrinol Metab 7 1978 625
42. Krauss R.M. Roy S. Mishell D.R. Jr. Effects of two low-dose oral contraceptives in serum lipids and lipoproteins: Differential changes in high-density lipoprotein subclasses Am J Obstet Gynecol 145 1983 446
43. Kushwaha R.S. Hazzard W.R. Gagne C. Type III hyperlipoproteinemia: Paradoxical hypolipidemic response to estrogen Ann Intern Med 87 1977 517
44. Lerner D.J. Kännel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population Am Heart J 111 1986 383
45. Lipid Research Clinics Population Studies Data Book, vol 1. The Prevalence Study. Bethesda, Maryland, US Dept Health Human Services, NIH publ no 80-1527, 1980
46. Lipson A. Stoy D.B. LaRosa J.C. Progestins and oral contraceptive-induced lipoprotein changes: A prospective study Contraception 34 1986 121
47. Mant D. Villard-Mackintosh L. Vessey M.P. Myocardial infarction and angina pectoris in young women J Epidemiol Community Health 41 1987 217
48. März W. Gross W. Gähn G. A randomized crossover comparison of two low-dose contraceptives: Effects on serum lipids and lipoproteins Am J Obstet Gynecol 153 1985 287
49. Matthews KA, Meilahn E, Kuller LH, et al: Changes in cardiovascular risk factors during the menopause (abstract). 29th Annual Meeting of the AHA Council on Epidemiology, Washington, DC, June 18-22, 1989
50. McNamara J.R. Campos J. Ordovas J.M. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: Results from the Framingham Offspring Study Arteriosclerosis 7 1987 483
51. Meilahn EN, Kuller LH, Matthews KA, et al: Change in lipoprotein lipids and apoproteins during the perimenopause (abstract). 29th Annual Meeting of AHA Council on Epidemiology, Washington, DC, June 18-22, 1989
52. Meusing RA, Miller VT, LaRosa JC: Effects of unopposed conjugated equine estrogen on lipoprotein metabolism and composition. Submitted for publication, 1990
53. Miller VT, Meusing RA, Stoy DB, et al: Lipids and lipoproteins in postmenopausal women: A prospective 12 month study of two doses of conjugated equine estrogen with medroxyprogesterone acetate. Submitted for publication, 1990
54. Miller VT, Meusing RA, LaRosa JC, et al: Effects of conjugated equine estrogen with and without three different progestogens on lipoprotein and apolipoproteins. Submitted for publication, 1990
55. Newman W.P. Freedman D.S. Voors A.W. Relation of serum lipoproteins and systolic blood pressure of early atherosclerosis: The Bogalusa Heart Study N Engl J Med 314 1986 138
56. Notelovitz M. Feldman E.B. Gillespy M. Lipids and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: A controlled comparative, 12-month clinical trial Am J Obstet Gynecol 160 1989 1269
57. Oliver M.F. Ischemic heart disease in young women Br Med J 4 1974 253
58. Ottosson U.B. Johansson B.G. von Schoulz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone Am J Obstet Gynecol 151 1985 746
59. Porter J.B. Jick H. Walker A.M. Mortality among oral contraceptive users Obstet Gynecol 70 1987 29
60. Potter J.M. Nestel P.J. The hyperlipidemia of pregnancy in normal and complicated pregnancies Am J Obstet Gynecol 133 1979 165
61. Prough S.G. Aksel S. Wiebe R.H. Continuous estrogen/progestin therapy in the menopause Am J Obstet Gynecol 157 1987 1449
62. Realini J.P. Goldzieher J.W. Oral contraceptives and cardiovascular disease: A critique of epidemiological studies Am J Obstet Gynecol 151 1985 729
63. Rosenberg L. Miller D.R. Kaufman D.W. Myocardial infarction in women under 50 years of age JAMA 250 1983 2801
64. Royal College of General Practitioners' Oral Contraceptive Study: Mortality among oral contraceptive users Lancet 2 1977 727
65. Runnebaum B. Rabe T. New progestogens in oral contraceptives Am J Obstet Gynecol 157 1987 1059
66. Sherwin B.B. Gelfand M.M. A prospective one-year study of estrogen and progestin in postmenopausal women: Effects on clinical symptoms and lipoprotein lipids Obstet Gynecol 73 1990 759
67. Shoupe D. Mishell D.R. Norplant: Subdermal implant system for long-term contraception Am J Obstet Gynecol 160 1989 1286
68. Slone D. Shapiro S. Kaufman D.W. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives N Engl J Med 305 1981 420
69. Stadel B.V. Oral contraceptives and cardiovascular disease N Engl J Med 305 1981 612
70. Stampfer M.G. Willett W.C. Colditz G.A. A prospective study of postmenopausal estrogen therapy and coronary heart disease N Engl J Med 313 1985 1044
71. Stampfer M.J. Willett W.C. Colditz G.A. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases N Engl J Med 319 1988 1313
72. Stanczyk F.Z. Shoupe D. Nunez V. A randomized comparison of non oral estradiol delivery in postmenopausal women Am J Obstet Gynecol 159 1988 1540
73. Stokes J. Kännel W.B. Wolf P.A. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framinham Study Circulation 75 suppl V 1987 V65
74. Thom T.J. Cardiovascular disease mortality among United States women Eaker E. Packard B. Wenger N. Coronary Heart Disease in Women 1987 Haymarket Doyma New York 33
75. Tikkänen M.J. Kuusi T. Vartianen E. Treatment of postmenopausal hypercholester olemia with estradiol Acta Obstet Gynecol Scand Suppl 88 1979 83
76. Tikkänen M.J. Nikkila E.A. Natural oestrogen as an effective treatment for type II hyperlipoproteinaemia in postmenopausal women Lancet 2 1977 490
77. Vecchia C.L. Decarli A. Franceschi S. Menstrual and reproductive factors and the risk of myocardial infarction in women under fifty-five years of age Am J Obstet Gynecol 157 1987 1108
78. Weinstein L. Efficacy of a continuous estrogen progestin regimen in the menopausal patient Obstet Gynecol 69 1987 929
79. Willett W.C. Green A. Stampfer M.J. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes N Engl J Med 317 1987 1303
80. Woods M. Schaefer E.J. Morrill A. Effect of menstrual cycle phase on plasma lipids J Clin Endocrinol Metab 65 1987 321
81. Zeil H.K. Finkle W.E. Increased risk of endometrial carcinoma among users of conjugated estrogens N Engl J Med 293 1975 1167
82. Zorrilla E. Hülse M. Hernandez A. Severe endogenous hypertriglyceridemia during treatment with estrogen and contraceptives J Clin Endocrinol 28 1968 1793